EA201700187A1 - Способ получения композиции, содержащей энтеровирусные частицы - Google Patents

Способ получения композиции, содержащей энтеровирусные частицы

Info

Publication number
EA201700187A1
EA201700187A1 EA201700187A EA201700187A EA201700187A1 EA 201700187 A1 EA201700187 A1 EA 201700187A1 EA 201700187 A EA201700187 A EA 201700187A EA 201700187 A EA201700187 A EA 201700187A EA 201700187 A1 EA201700187 A1 EA 201700187A1
Authority
EA
Eurasian Patent Office
Prior art keywords
obtaining
composition containing
cipv
containing enterovirus
enterovirus particles
Prior art date
Application number
EA201700187A
Other languages
English (en)
Inventor
Раджив Мхаласакант Дхири
Самбхаджи Шанкар Пизал
Джагдиш Камаладжи Зади
Раджендра Нараян Сабали
Original Assignee
Серум Инститьют Оф Индиа Прайвит Лимитид
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Серум Инститьют Оф Индиа Прайвит Лимитид filed Critical Серум Инститьют Оф Индиа Прайвит Лимитид
Publication of EA201700187A1 publication Critical patent/EA201700187A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32663—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32671—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к усовершенствованным способам инактивации энтеровирусов формальдегидом в присутствии трометамин-буфера, обеспечивающим максимальное восстановление антигена D. Последующая адсорбция упомянутых сИПВ на гидрооксиде алюминия позволяет применять составы сИПВ с существенно сниженной дозой.
EA201700187A 2014-10-07 2015-10-06 Способ получения композиции, содержащей энтеровирусные частицы EA201700187A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3180MU2014 2014-10-07
PCT/IN2015/000376 WO2016063291A1 (en) 2014-10-07 2015-10-06 Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Publications (1)

Publication Number Publication Date
EA201700187A1 true EA201700187A1 (ru) 2017-12-29

Family

ID=55300742

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201700187A EA201700187A1 (ru) 2014-10-07 2015-10-06 Способ получения композиции, содержащей энтеровирусные частицы

Country Status (23)

Country Link
US (1) US10485862B2 (ru)
EP (2) EP3204494B1 (ru)
JP (2) JP6755243B2 (ru)
KR (2) KR102510744B1 (ru)
CN (2) CN106999569B (ru)
AU (2) AU2015334495B2 (ru)
CA (1) CA2963897C (ru)
CU (1) CU24510B1 (ru)
CY (1) CY1123078T1 (ru)
DK (1) DK3204494T3 (ru)
EA (1) EA201700187A1 (ru)
ES (1) ES2803578T3 (ru)
HU (1) HUE049104T2 (ru)
LT (1) LT3204494T (ru)
MX (1) MX2017004534A (ru)
PE (1) PE20171132A1 (ru)
PH (1) PH12017500627A1 (ru)
PL (1) PL3204494T3 (ru)
PT (1) PT3204494T (ru)
SG (2) SG11201702838SA (ru)
SI (1) SI3204494T1 (ru)
UA (1) UA125788C2 (ru)
WO (1) WO2016063291A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049104T2 (hu) * 2014-10-07 2020-08-28 Serum Institute Of India Pvt Ltd Javított eljárások poliovírus inaktiválására, adjuváns adszorpciója
CA3022602A1 (en) * 2016-05-10 2017-11-16 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
SG11201900365WA (en) * 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition
TWI711700B (zh) * 2017-07-10 2020-12-01 印度商印度血清研究公司 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物
CN111511395B (zh) 2017-11-03 2024-10-15 武田疫苗股份有限公司 用于将寨卡病毒灭活和用于确定灭活完全性的方法
JP2021505549A (ja) 2017-11-30 2021-02-18 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ジカワクチン及び免疫原性組成物、ならびにその使用方法
SG11202007503WA (en) * 2018-02-07 2020-09-29 Bharat Biotech Int Ltd A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
CN109550046B (zh) * 2018-12-21 2020-08-25 北京民海生物科技有限公司 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2194531C2 (ru) * 1996-07-02 2002-12-20 Коннот Лабораториз Лимитед Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины
WO2007007344A1 (en) * 2004-08-27 2007-01-18 Panacea Biotec Ltd. Inactivated poliomyelitis vaccine derived from sabin strain of polio virus
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
MX2009002560A (es) * 2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vacuna.
CN100540662C (zh) * 2006-12-06 2009-09-16 云南沃森生物技术有限公司 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
BR112012014689B1 (pt) * 2009-12-16 2019-11-12 Serum Institute Of India Private Limited composição imunogênica
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
HUE049104T2 (hu) 2014-10-07 2020-08-28 Serum Institute Of India Pvt Ltd Javított eljárások poliovírus inaktiválására, adjuváns adszorpciója

Also Published As

Publication number Publication date
CY1123078T1 (el) 2021-10-29
CN106999569A (zh) 2017-08-01
CN106999569B (zh) 2021-06-29
CU20170044A7 (es) 2018-09-05
US20170348411A1 (en) 2017-12-07
JP7063957B2 (ja) 2022-05-09
PL3204494T3 (pl) 2020-09-21
JP2017533899A (ja) 2017-11-16
JP2020203906A (ja) 2020-12-24
JP6755243B2 (ja) 2020-09-16
KR20170063947A (ko) 2017-06-08
CA2963897A1 (en) 2016-04-28
AU2021269395A1 (en) 2021-12-16
MX2017004534A (es) 2017-10-11
AU2021269395B2 (en) 2024-05-23
BR112017007089A2 (pt) 2017-12-26
HUE049104T2 (hu) 2020-08-28
KR20210021148A (ko) 2021-02-24
EP3204494A1 (en) 2017-08-16
SG10202010814RA (en) 2020-12-30
SI3204494T1 (sl) 2020-08-31
CA2963897C (en) 2023-08-22
KR102510744B1 (ko) 2023-03-15
EP3663396A1 (en) 2020-06-10
NZ731341A (en) 2023-11-24
AU2015334495B2 (en) 2021-08-19
KR102219638B1 (ko) 2021-02-23
US10485862B2 (en) 2019-11-26
ES2803578T3 (es) 2021-01-28
PE20171132A1 (es) 2017-08-09
PT3204494T (pt) 2020-07-10
CN113368227A (zh) 2021-09-10
CU24510B1 (es) 2021-05-12
WO2016063291A1 (en) 2016-04-28
EP3204494B1 (en) 2020-04-01
LT3204494T (lt) 2020-07-10
PH12017500627A1 (en) 2017-09-25
AU2015334495A1 (en) 2017-05-25
SG11201702838SA (en) 2017-05-30
UA125788C2 (uk) 2022-06-08
DK3204494T3 (da) 2020-07-06

Similar Documents

Publication Publication Date Title
EA201700187A1 (ru) Способ получения композиции, содержащей энтеровирусные частицы
PH12016501763A1 (en) Multispecific antibodies
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201691556A1 (ru) Молекулы антител к tim-3 и их применение
EA201790380A1 (ru) Ингибиторы mk2 и их применения
SG11201607030PA (en) Antibodies, uses & methods
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
MX2023006415A (es) Anticuerpos, usos y metodos.
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
EA201690036A1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
EA201692534A1 (ru) Способы лечения гипотонии
IN2014MU00455A (ru)
EA201591709A1 (ru) 5-бром-индирубины
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
TWD175367S (zh) 自行車用頭燈
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
TH1501007899B (th) วัสดุผสมดูดซึม, วิธีการสำหรับการทำวัสดุผสมดูดซึม, และผลิตภัณฑ์ดูดซึมซึ่งใช้วัสดุผสมดูดซึม
TW201613927A (en) Method for preparation of substituted imidazopyridazines
UA96801U (uk) Спосіб обробки водно-спиртової суміші
TH1601000279B (th) เครื่องและวิธีการสำหรับลงรหัสเมทาดาทาอ็อบเจกต์ที่มีประสิทธิภาพ
TH1601003349A (th) สารกระจายตัวที่มีอนุภาคกราฟินิก คาร์บอน และวิธีการทำดังกล่าว
TWD164575S (zh) 眼鏡
TN2014000522A1 (fr) لوح مدرسي بوجهين
TR201401766A2 (tr) Asteninin tedavisine yönelik bir kompozisyon.
GB201413950D0 (en) Antibodies, uses & methods